FactaeThe Factual News

Sanofi's venglustat granted priority review status in the US

Sanofi's venglustat benefits from priority review procedure with the US FDA, accelerating its processing.

Published 11sem1 sourceNotableupdated 3j
Lire en français
≈ 19s

The fact

This decision strengthens the group's therapeutic prospects in rare genetic and metabolic diseases.

Accelerated approval could lead to faster market launch of the treatment.

Click the link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
États-UnisWorld map →
Follow topic →
Auto-synthesis from 1 media source · identified on May 28, 2026
← Back to home
Discover

Read more

All marches →
sante

Sanofi awaits FDA decision on license application

16sem · 1 sourceeconomie

Sanofi receives EU approval for its first anti-cancer drug

9sem · 1 sourcemarches

Sanofi confirms the efficacy of its Nexviazyme treatment

6sem · 1 sourcesante

Sanofi wins EU approval for innovative cancer treatment with portable injector

9sem · 1 sourceeconomie

Sanofi halts late-stage clinical trial in major strategic reversal

9sem · 1 sourcesante

United States approves first gene therapy against a rare disease

16sem · 1 source